News

Celiprolol Treatment Linked to Improved Survival in vEDS Patients

The therapy celiprolol increased the survival rate and possibly lowered annual incidence of arterial events in patients with vascular Ehlers-Danlos syndrome (vEDS), according to results of a long-term study announced by Acer Therapeutics. The results were published in the Journal of the American College of Cardiology, in…

Molecular Analysis Pinpoints Pathways Underlying Defects in cEDS

Gene expression analysis of skin cells identified several molecular pathways deregulated in classical Ehlers-Danlos syndrome (cEDS) patients, which may open new avenues for therapeutics, according to a new study. The study, “Molecular insights in the pathogenesis of classical Ehlers-Danlos syndrome from transcriptome-wide expression profiling of patients’ skin fibroblasts,” was…